Poland· PL-100316295
Ryzodeg
A insulin degludec und insulin aspart product containing insulinum degludecum + insulinum aspartum, registered in Poland by Novo Nordisk A/S. The same ATC class is registered in 9 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Insulin degludec und insulin aspart is registered in 9 of 19 countries.
Countries holding a registration under ATC A10AD06 (insulin degludec und insulin aspart), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Insulin degludec und insulin aspart · ATC A10AD06
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Insulinum degludecum + Insulinum aspartum
- Manufacturer
- Novo Nordisk A/S
- Country
- Poland (PL)
- ATC code
- A10AD06
- ATC class
- Insulin degludec und Insulin aspart
- Defined daily dose
- 40 E, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
1 priced- gtin05909991414016
- gtin05909991416638
- gtin059099913715625 wkł.po 3 mlPLN 174.38
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Insulin degludec und insulin aspart in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaRYZODEGNovo Nordisk A/S, Bagsvaerd
- SwedenRyzodeg FlexPen 100 enheter/ml Injektionsvätska, lösning i förfylld injektionspennaNovo Nordisk A/S
- FinlandRyzodeg FlexPenNovo Nordisk A/S
- SwitzerlandRyzodeg FlexTouch , InjektionslösungNovo Nordisk Pharma AG
- IcelandRyzodegNovo Nordisk A/S*
- NetherlandsRyzodeg 100 eenheden/ml oplossing voor injectie in patroonNovo Nordisk A.S.
- IrelandRyzodeg 100 units/mL solution for injectionNovo Nordisk A/S
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Ryzodeg Flexpen, Ryzodeg Flextouch
- Norway · Ryzodeg Flexpen, Ryzodeg Flextouch
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1fb068e7-36f0-46c5-94cc-17a07c7b6e82 GET /v1/drugs/1fb068e7-36f0-46c5-94cc-17a07c7b6e82?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "100 j./ml",
"packaging": "Rp ¦ EU/1/12/806/001 ¦ 91518\n1 wstrzykiwacz 3 ml\nRp ¦ EU/1/12/806/002 ¦ 91519\n1 wstrzykiwacz 3 ml ¦ 7 igieł NovoFine\n05909991371562 ¦ Rp ¦ EU/1/12/806/007 ¦ 91520\n5 wkładów 3 ml\nRp ¦ EU/1/12/806/003 ¦ 91521\n1 wstrzykiwacz 3 ml ¦ 7 igieł NovoTwist\nRp ¦ EU/1/12/806/005 ¦ 91522\n10 wstrzykiwaczy 3 ml\n05909991414016 ¦ Rp ¦ EU/1/12/806/008 ¦ 91523\n10 wkładów 3 ml\n05909991416638 ¦ Rp ¦ EU/1/12/806/004 ¦ 91524\n5 wstrzykiwaczy 3 ml\nRp ¦ EU/1/12/806/009 ¦ 160041\n5 wstrzyk. 3 ml",
"substance": "Insulinum degludecum 2.56 mg/1 ml + Insulinum aspartum 1.05 mg/1 ml",
"common_name": "Insulinum degludecum + Insulinum aspartum",
"pl_product_id": "100316295",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about insulin degludec und insulin aspart.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.